Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Articles online first > Journal of Neurosurgical Sciences 2022 Apr 05



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as


Original Article   

Journal of Neurosurgical Sciences 2022 Apr 05

DOI: 10.23736/S0390-5616.22.05552-7


language: English

Interleukin-17 receptor D is a favorable biomarker of glioblastoma

Yang LIU 1, Mingshui XIE 1, Ye ZHOU 2, Lili CHE 2, Bin ZHANG 3

1 Department of Laboratory Medicine, Suizhou Hospital, HuBei University Of Medicine Of the People's Republic of China, Weifang, China; 2 Departments of Neurosurgery, Weifang Central Hospital, Weifang, Shandong, China; 3 Departments of Neurosurgery, Taian Municipal Hospital, Taian, Shandong, China


BACKGORUND: Glioblastoma (GBM) is the most frequent glioma in adults. The prognosis of GBM is very poor and new prognostic biomarkers are in urgent need to better select high-risk patients and guide the individual treatments.
METHODS: In our study, we compared the expression of Interleukin-17 receptor D (IL17RD) between GBMs and normal tissues from TCGA database, and detected IL17RD mRNA in 17 fresh GBM pairs with qPCR. With immunohistochemistry, we investigated the expression of IL17RD in 156 GBM tissues and further evaluated its clinical significance. The associations between IL17RD and clinicopathological factors were assessed by chi-square test. The prognostic significance of IL17RD was evaluated by univariate analysis with Kaplan-Meier method, and by multivariate analysis with Cox-regression Hazard model.
RESULTS: The TPMs and mRNAs of IL17RD in GBM were substantially lower than those in normal brain tissues. The rates of low or high expression of IL17RD accounted for 41.67% and 58.33% respectively. IL17RD was significantly associated with higher survival rates of GBM. The 3-year overall survival rates of patients with low and high IL17RD were 7.2% and 19.5% respectively. In the Cox-regression model, the IL17RD expression was defined as an independent prognostic biomarker of GBM. Patients with high IL17RD expression had a more favorable outcome than those with low IL17RD.
CONCLUSIONS: High IL17RD expression was an independent prognostic indicator of GBM, suggesting a more favorable prognosis. Our results suggested that IL17RD detection may help find the high-risk patients which may receive more severe surveillance and more individual treatments.

KEY WORDS: Interleukin-17 receptor D; Glioblastoma; Prognosis; Biomarker

top of page